Celyad Oncology Balance Sheet Health
Financial Health criteria checks 4/6
Celyad Oncology has a total shareholder equity of €3.3M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €12.8M and €9.6M respectively.
Key information
0%
Debt to equity ratio
€0
Debt
| Interest coverage ratio | n/a |
| Cash | €6.23m |
| Equity | €3.27m |
| Total liabilities | €9.58m |
| Total assets | €12.85m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: CYAD's short term assets (€8.7M) exceed its short term liabilities (€2.4M).
Long Term Liabilities: CYAD's short term assets (€8.7M) exceed its long term liabilities (€7.2M).
Debt to Equity History and Analysis
Debt Level: CYAD is debt free.
Reducing Debt: CYAD has no debt compared to 5 years ago when its debt to equity ratio was 0.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYAD has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CYAD has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.8% each year.